AbCellera Biologics Inc. (ABCL)

NASDAQ: ABCL · USD

$13.6

+0.81 (+6.3%)· Recorded snapshot

Market cap	4.4B
Revenue (ttm)	66.2M
Net income (ttm)	-164.7M
EPS (ttm)	-$0.55
Shares out	324M
Volume	2,869,753
Beta	1.41

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 66.2M
Net income (ttm): -164.7M
EPS (ttm): -$0.55
Market cap: 4.4B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-17.3

P25 n/aP50 n/aP75 n/a

ROIC-42.3

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ABCL indicators

Market & fundamental data

Available fields

202

Groups with data

Currency

USD

Showing 202 of 202 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001703057
Company name	AbCellera Biologics Inc.
Country	Canada
Country code	US
CUSIP number	00288U106
Earnings date	2026-11-09
Earnings time	amc
Employees	562
Employees change	-34
Employees growth	-5.7%
Enterprise value	$4B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2012
Industry	Biotechnology
IPO date	2020-12-11
Is primary listing	Yes
Is SPAC	No
ISIN number	CA00288U1066
Last 10-K release date	2026-02-24
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$4.4B
Market cap category	Mid-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$13.64
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	ABCL
Website	https://www.abcellera.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-4%
EV/Sales	59.31x
FCF / EV yield	-3.05%
FCF yield	-2.76%
Forward EV/Sales	108.59x
Forward P/S	119.78x
P/B ratio	4.39x
P/S ratio	65.43x
Price / tangible book value	5.33x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	-198.88%
Operating margin	-340.27%
Pretax margin	-297.37%
Profit margin	-248.84%
Profit per employee	$-292,982
Revenue per employee	$117,740
ROA	-10.39%
ROA (5Y)	-2.27%
ROCE	-17.95%
ROE	-17.3%
ROE (5Y)	-2.19%
ROIC	-42.28%
ROIC (5Y)	-12.85%
SBC / revenue	77.22%
Tax / revenue	-48.53%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	1
Net income growth years	1
Revenue growth	101.27%
Revenue growth (Q)	-76.29%
Revenue growth (QoQ)	-51.29%
Revenue growth 3Y	-23.04%
Revenue growth 5Y	-31.77%
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-24.7M
Depreciation and amortization	$25.2M
EBIT	$-225.2M
EBITDA	$-200M
EPS	$-0.55
FCF per share	$-0.37
Financing cash flow	$25.1M
Free cash flow	$-119.7M
Free cash flow minus SBC	$-170.8M
Gross profit	$-131.6M
Income taxes	$-32.1M
Investing cash flow	$97.9M
Net borrowing	$29.7M
Net cash flow	$27.3M
Net income	$-164.7M
Operating cash flow minus SBC	$-146M
Operating income	$-225.2M
Revenue	$66.2M
Stock-based compensation	$51.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	1.83
Book value per share	$2.92
Debt / equity	0.15
Goodwill	$47.8M
Long-term assets	$628.3M
Long-term liabilities	$358.4M
Net cash (debt)	$404.5M
Net cash / market cap	9.34%
Net cash growth	-1.58%
Net debt / equity	-0.45
Piotroski F-Score	4
Property, plant and equipment	$416.7M
Shareholders' equity	$896M
Tangible book value	$811.7M
Tangible book value per share	$2.65
Total assets	$1.3B
Total cash	$540.1M
Total debt	$135.6M
Total liabilities	$411.6M
WACC	11.64%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.05
Current assets	$679.2M
Current liabilities	$53.2M
Current ratio	12.77
Net working capital	$91.6M
Quick ratio	11.23
Working capital	$626M
Working capital turnover	0.1

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-1.74%
Dividend yield	0%
Shareholder yield	-1.74%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$7.83
1D price change	6.31%
1M price change	6.06%
1M total return	6.06%
1W price change	15.03%
1W total return	15.03%
1Y price change	133.45%
1Y return CAGR	133.59%
1Y total return	133.45%
20-day SMA	$12.58
200-day SMA	$6.77
3M price change	156.57%
3M total return	156.57%
3Y price change	244.5%
3Y return CAGR	51.02%
3Y total return	244.5%
50-day SMA	$12.25
50-day SMA vs 200-day SMA	50over200
52-week high	$15.02
52-week high date	2026-09-30
52-week low	$2.75
52-week low date	2026-02-05
5Y price change	-12.36%
5Y return CAGR	-2.6%
5Y total return	-12.36%
6M price change	223.8%
6M total return	223.8%
All-time high	$71.91
All-time high date	2020-12-11
All-time low	$1.89
All-time low date	2025-04-07
Average true range (ATR)	$0.82
Average volume	4.6M
Beta (1Y)	2.7
Beta (2Y)	1.89
Beta (5Y)	1.41
Change from 52-week high	-9.16%
Change from 52-week low	396.9%
Change from all-time high	-81.27%
Change from all-time low	612.32%
Change from open	6.81%
Day's gap	-0.47%
Dollar volume	$39.1M
High price	$13.65
Low price	$12.67
Monthly RSI	68.64
Open price	$12.77
Position in 52-week range	98.98%
Premarket change	-0.23%
Premarket close	$12.83
Premarket price	$12.80
Previous close	$12.83
Price vs 150-day SMA	71.94%
Price vs 20-day SMA	7.11%
Price vs 200-day SMA	99.05%
Price vs 50-day SMA	9.98%
Relative volume	0.62
Return from IPO open	-78.1%
Return from IPO price	-33.2%
RSI	59.58
Sharpe ratio	1.36
Sharpe ratio (3Y)	0.82
Sharpe ratio (5Y)	0.23
Sortino ratio	2.39
Sortino ratio (3Y)	1.45
Sortino ratio (5Y)	0.46
Volume	2.9M
Weekly RSI	70.07
YTD price change	293.86%
YTD total return	293.86%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	220.9M
Float percentage	68.18%
Shares change (QoQ)	0.82%
Shares change (YoY)	1.74%
Shares held by insiders	21.64%
Shares held by institutions	25.99%
Shares outstanding	324M
Short % of float	14%
Short % of shares	9.55%
Short ratio	7 days

Deeper analysis on ABCL

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ABCL report

Is a complete ABCL research report available?

No complete published report is available for AbCellera Biologics Inc. (ABCL) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

AbCellera Biologics Inc. (ABCL)

Price

Financial snapshot

Fair-value bridge

Latest news · ABCL

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ABCL indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ABCL

Frequently asked questions